Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Název česky Efektivita Sunitinibu v léčbě starších pacientů s metastatickým nádorem ledviny: Data z klinické praxe
Autoři

POPRACH Alexandr LAKOMÝ Radek BORTLÍČEK Zbyněk MELICHAR Bohuslav PAVLÍK Tomáš SLABÝ Ondřej VYZULA Rostislav SVOBODA Marek KISS Igor STUDENTOVA Hana ZEMANOVA Milada FIALA Ondrej KUBACKOVA Katerina DUŠEK Ladislav HORNOVA Jana BUCHLER Tomas

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Drugs & Aging
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1007/s40266-016-0390-1
Obor Farmakologie a lékárnická chemie
Klíčová slova INTERFERON-ALPHA; SAFETY; CANCER
Popis Background Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. Patients and Methods The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged < 70 and aeyen70 years, respectively. Results Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged < 70 and aeyen70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. Conclusions The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.